[go: up one dir, main page]

CN118903551A - Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection - Google Patents

Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection Download PDF

Info

Publication number
CN118903551A
CN118903551A CN202410966599.8A CN202410966599A CN118903551A CN 118903551 A CN118903551 A CN 118903551A CN 202410966599 A CN202410966599 A CN 202410966599A CN 118903551 A CN118903551 A CN 118903551A
Authority
CN
China
Prior art keywords
gel
sodium hyaluronate
cross
microspheres
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410966599.8A
Other languages
Chinese (zh)
Inventor
郑茜仁
吴顺利
赵鑫
孙伟庆
贾倩倩
朱美琴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Singclean Medical Products Co Ltd
Original Assignee
Hangzhou Singclean Medical Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Singclean Medical Products Co Ltd filed Critical Hangzhou Singclean Medical Products Co Ltd
Priority to CN202410966599.8A priority Critical patent/CN118903551A/en
Publication of CN118903551A publication Critical patent/CN118903551A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/06Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection, which introduces a freeze-drying process, through the chemical crosslinking modularized treatment of the sodium hyaluronate in the environment of-50 to-80 ℃, the solid storage of the crosslinked gel is realized. The preparation process can modularly treat the crosslinked gel through single mass production, can be used for subsequent multiple times, and can directly load the microspheres after re-dissolution according to the requirement. Compared with the traditional gel preparation process, the preparation process can directly compound the crosslinked gel and the microspheres, increases the flexibility and convenience of process operation, and after the crosslinked gel is freeze-dried and modularized, the crosslinked sodium hyaluronate gel is stored in a solid state, so that the crosslinked sodium hyaluronate gel can be taken and used at any time, and the gel system can still keep stable physical and chemical properties after being redissolved, thereby ensuring the effectiveness of the product.

Description

一种注射用装载可降解微球的透明质酸钠复合凝胶的模块化 制备方法Modular preparation method of a sodium hyaluronate composite gel loaded with degradable microspheres for injection

技术领域Technical Field

本发明涉及一种注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法。The invention relates to a modular preparation method of a sodium hyaluronate composite gel loaded with degradable microspheres for injection.

背景技术Background Art

近年来,可注射凝胶体系在注射部位起到填充和再生的美容作用和实现微创治疗如鼻唇沟,以及人类免疫缺陷病毒(HIV)患者脂肪减退的恢复和/或矫正等。目前市面上的填充再生产品多为交联或非交联透明质酸钠凝胶复合再生微球,例如:聚乳酸(PLA)、左旋聚乳酸(PLLA)、聚己内酯(PCL)、羟基磷灰石(CaHA)等。In recent years, injectable gel systems have played a cosmetic role in filling and regenerating the injection site and achieved minimally invasive treatments such as nasolabial folds, and restoration and/or correction of fat loss in human immunodeficiency virus (HIV) patients. Currently, most of the filling and regeneration products on the market are cross-linked or non-cross-linked sodium hyaluronate gel composite regeneration microspheres, such as polylactic acid (PLA), poly-L-lactic acid (PLLA), polycaprolactone (PCL), hydroxyapatite (CaHA), etc.

专利CN201510593332.X公开了微球和交联透明酸钠混合凝胶的制备方法,专利中将微球材料与交联透明质酸钠凝胶混合制备凝胶微球复合体。专利所述方法中交联后凝胶直接与微球材料复合,制备过程具有延续性,无法做到随取随用。因此,需进一步调整交联透明质酸钠凝胶复合微球的制备工艺。Patent CN201510593332.X discloses a method for preparing a mixed gel of microspheres and cross-linked sodium hyaluronate. In the patent, the microsphere material is mixed with the cross-linked sodium hyaluronate gel to prepare a gel-microsphere complex. In the method described in the patent, the gel is directly compounded with the microsphere material after cross-linking. The preparation process is continuous and cannot be used as needed. Therefore, it is necessary to further adjust the preparation process of the cross-linked sodium hyaluronate gel composite microspheres.

发明内容Summary of the invention

本发明的目的是提供一种注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法。本技术引入冻干工艺,将交联透明质酸钠进行冻干模块化处理,单次批量生产,以固态储存,实现交联透明质酸的即用即取,提升工艺灵活性。本发明是通过以下技术方案来实现的;The purpose of the present invention is to provide a modular preparation method for a sodium hyaluronate composite gel loaded with degradable microspheres for injection. This technology introduces a freeze-drying process, freeze-drying the cross-linked sodium hyaluronate in a modular manner, produces a single batch, and stores it in a solid state, so that the cross-linked hyaluronic acid can be used immediately and the process flexibility is improved. The present invention is achieved through the following technical solutions;

本发明公开了一种注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,包括如下步骤:The present invention discloses a modular preparation method of a sodium hyaluronate composite gel loaded with degradable microspheres for injection, comprising the following steps:

1)透明质酸钠在碱性溶液中溶解后进行交联反应,并将交联形成的透明质酸钠凝胶透析4~8天后进行冷冻干燥得到冻干凝胶;1) Sodium hyaluronate is dissolved in an alkaline solution and then cross-linked, and the cross-linked sodium hyaluronate gel is dialyzed for 4 to 8 days and then freeze-dried to obtain a freeze-dried gel;

2)将冻干凝胶粉碎为凝胶微粒,将凝胶微粒以一定浓度充分复溶后,得到交联凝胶,在交联凝胶中加入特定比例的微球及透明质酸钠溶液混合均匀得混合凝胶;2) crushing the freeze-dried gel into gel particles, fully re-dissolving the gel particles at a certain concentration to obtain a cross-linked gel, adding microspheres and sodium hyaluronate solution in a specific ratio to the cross-linked gel and mixing them evenly to obtain a mixed gel;

3)将混合凝胶灌装至预灌封注射器中,进行高压蒸汽灭菌,得到注射用装载可降解微球的透明质酸钠复合凝胶。3) Filling the mixed gel into a pre-filled syringe and sterilizing it with high-pressure steam to obtain a sodium hyaluronate composite gel loaded with degradable microspheres for injection.

作为进一步地改进,本发明所述的交联凝胶的冷冻干燥温度为-50~-80℃,存储温度为0~-80℃,冻干凝胶的复溶溶液为磷酸缓冲盐或生理盐水,pH为6.8~7.5,渗透压为280~340mOsm/L。As a further improvement, the freeze-drying temperature of the cross-linked gel of the present invention is -50 to -80°C, the storage temperature is 0 to -80°C, the reconstitution solution of the freeze-dried gel is phosphate buffered saline or physiological saline, the pH is 6.8 to 7.5, and the osmotic pressure is 280 to 340 mOsm/L.

作为进一步地改进,本发明所述的微球材料占混合凝胶的质量分数为5~30%;微球材料的平均粒径为10~100μm。As a further improvement, the mass fraction of the microsphere material of the present invention in the mixed gel is 5 to 30%; the average particle size of the microsphere material is 10 to 100 μm.

作为进一步地改进,本发明所述的碱性溶液为氢氧化钠、氢氧化钾中的任意一种,溶液浓度为0.1~5.0mol/L。As a further improvement, the alkaline solution described in the present invention is any one of sodium hydroxide and potassium hydroxide, and the solution concentration is 0.1-5.0 mol/L.

作为进一步地改进,本发明所述的步骤2)中加入的透明质酸钠的分子量为500,000~3,000,000Da,交联凝胶中透明质酸钠的浓度为1~15%,透明质酸钠在混合凝胶中的质量分数为1~50%。As a further improvement, the molecular weight of the sodium hyaluronate added in step 2) of the present invention is 500,000 to 3,000,000 Da, the concentration of sodium hyaluronate in the cross-linked gel is 1 to 15%, and the mass fraction of sodium hyaluronate in the mixed gel is 1 to 50%.

作为进一步地改进,本发明所述的步骤1)中的透明质酸钠凝胶交联反应所用的交联剂为二乙烯基砜、1,4-丁二醇二缩水甘油醚、乙二酸二酰肼、碳二亚胺、甲基丙烯酸缩水甘油酯中的一种或多种,浓度为0.1~10mg/mL。As a further improvement, the cross-linking agent used in the cross-linking reaction of the sodium hyaluronate gel in step 1) of the present invention is one or more of divinyl sulfone, 1,4-butanediol diglycidyl ether, oxalic acid dihydrazide, carbodiimide, and glycidyl methacrylate, with a concentration of 0.1 to 10 mg/mL.

作为进一步地改进,本发明所述的步骤2)中微球分批、多次加入凝胶体系,在100~800rpm/min下搅拌4~16小时,且每隔20~50分钟手动搅拌一次,使复合凝胶体系均匀混合。As a further improvement, in step 2) of the present invention, the microspheres are added to the gel system in batches and multiple times, stirred at 100-800 rpm/min for 4-16 hours, and manually stirred every 20-50 minutes to uniformly mix the composite gel system.

作为进一步地改进,本发明所述的透明质酸钠凝胶成分包括透明质酸钠、交联透明质酸钠,透明质酸钠可替换为胶原蛋白、壳聚糖、明胶、海藻酸钠、纤维蛋白、丝素蛋白以及人工合成凝胶,人工合成凝胶为聚乙二醇、聚乙烯醇、聚氧乙烯、聚丙烯酰胺中的任意一种。As a further improvement, the sodium hyaluronate gel component described in the present invention includes sodium hyaluronate and cross-linked sodium hyaluronate. Sodium hyaluronate can be replaced by collagen, chitosan, gelatin, sodium alginate, fibrin, silk fibroin and artificial synthetic gel. The artificial synthetic gel is any one of polyethylene glycol, polyvinyl alcohol, polyethylene oxide and polyacrylamide.

作为进一步地改进,本发明所述的微球的材料为聚乳酸、聚左旋乳酸、聚己内酯、羟基磷灰石中的一种或几种的复合体。As a further improvement, the material of the microspheres described in the present invention is one or a composite of several of polylactic acid, poly-L-lactic acid, polycaprolactone and hydroxyapatite.

作为进一步地改进,本发明所述的步骤2)中在交联凝胶中还加入脂质体、外泌体、氨基酸、多肽、蛋白质、维生素及局部类麻醉剂等一种或多种活性成分。As a further improvement, in step 2) of the present invention, one or more active ingredients such as liposomes, exosomes, amino acids, polypeptides, proteins, vitamins and local anesthetics are also added to the cross-linked gel.

本发明涉及一种注射用装载可降解微球的透明质酸钠复合凝胶及其模块化制备方法,由可降解微球、交联透明质酸钠凝胶的盐溶液以及透明质酸钠流动相等组成。本发明以模块化组装的形式,引入冻干技术,透析后交联透明质酸钠凝胶进行冷冻干燥,将其粉碎并以一定浓度充分复溶后,装载微球,使其均匀分布于透明质酸钠凝胶中,制备微球凝胶复合体系。本发明实现了微球,交联透明质酸钠凝胶以及两者复合这三个过程的模块化制备。以固态储存交联凝胶,可实现交联凝胶的随取随用,提升工艺灵活性。本发明所制备的注射用复合凝胶注入人体局部组织后,起到改善和修饰面部软组织缺陷及组织轮廓的效果,随着微球的逐步降解,持续刺激胶原生长,保证其长效的填充效果。The present invention relates to a sodium hyaluronate composite gel loaded with degradable microspheres for injection and a modular preparation method thereof, which is composed of degradable microspheres, a salt solution of a cross-linked sodium hyaluronate gel, and a sodium hyaluronate mobile phase. The present invention introduces freeze-drying technology in the form of modular assembly, freeze-drying the cross-linked sodium hyaluronate gel after dialysis, crushing it and fully re-dissolving it at a certain concentration, loading microspheres, making it uniformly distributed in the sodium hyaluronate gel, and preparing a microsphere gel composite system. The present invention realizes the modular preparation of the three processes of microspheres, cross-linked sodium hyaluronate gel, and the composite of the two. The cross-linked gel is stored in a solid state, so that the cross-linked gel can be taken and used at any time, thereby improving the process flexibility. After the composite gel for injection prepared by the present invention is injected into the local tissue of the human body, it has the effect of improving and modifying the defects of facial soft tissues and tissue contours. With the gradual degradation of the microspheres, the collagen growth is continuously stimulated to ensure its long-term filling effect.

与现有技术相比,本发明的创新以及有益效果主要体现在:Compared with the prior art, the innovation and beneficial effects of the present invention are mainly reflected in:

(1)在该复合凝胶制备方法中,引入冻干工艺,通过将交联透明质酸钠凝胶置于-50~-80℃环境中,对透明质酸钠的化学交联模块化处理,实现了交联凝胶的固态存储。这种制备工艺可以通过单次大批量的生产,将交联凝胶模块化处理,可供后续多次取用,按需复溶后直接装载微球。与传统的凝胶制备工艺相比,该制备工艺可使交联凝胶与微球直接复配,增加了工艺操作的灵活性和便捷性。(1) In the composite gel preparation method, a freeze-drying process is introduced. By placing the cross-linked sodium hyaluronate gel in an environment of -50 to -80°C, the chemical cross-linking of sodium hyaluronate is modularized, thereby achieving solid-state storage of the cross-linked gel. This preparation process can modularize the cross-linked gel through a single large-scale production, so that it can be taken multiple times in the future and directly loaded with microspheres after re-dissolving as needed. Compared with the traditional gel preparation process, this preparation process can directly compound the cross-linked gel with the microspheres, increasing the flexibility and convenience of the process operation.

(2)将交联凝胶冻干模块化处理后,交联透明质酸钠凝胶以固态储存,可实现交联凝胶的随取随用,且复溶后凝胶体系仍能保持稳定的理化性能,从而保证产品的有效性。此外,该制备工艺也为后续交联凝胶冻干、复溶操作提供了更便捷可靠的方法。(2) After the cross-linked gel is freeze-dried and modularized, the cross-linked sodium hyaluronate gel is stored in a solid state, which allows the cross-linked gel to be taken and used at any time, and the gel system can still maintain stable physical and chemical properties after re-dissolution, thereby ensuring the effectiveness of the product. In addition, this preparation process also provides a more convenient and reliable method for the subsequent freeze-drying and re-dissolution operations of the cross-linked gel.

(3)将冻干凝胶微粒使用pH为6.8~7.5,渗透压为280~340mOsm/L磷酸缓冲液或生理盐水进行复溶,使该复合凝胶能更好的满足人体的生理适应条件,在体内环境中保持填充稳定性,提高其生物相容性,可以有效减少植入材料引起的炎症反应。(3) The freeze-dried gel particles are re-dissolved in a phosphate buffer solution or physiological saline with a pH of 6.8 to 7.5 and an osmotic pressure of 280 to 340 mOsm/L, so that the composite gel can better meet the physiological adaptation conditions of the human body, maintain filling stability in the in vivo environment, improve its biocompatibility, and effectively reduce the inflammatory response caused by the implant material.

本发明将交联透明质酸钠凝胶与可再生微球均匀混合,形成的混合凝胶注射入皮肤后,能取代流失的胶原蛋白,刺激人体内胶原蛋白的再生,效果显著且持久。本发明提供的注射用装载可降解微球的透明质酸钠复合凝胶产品颗粒均匀细腻,易于注射,在局部作用时间长,可塑性好,填充效果明显。The present invention uniformly mixes cross-linked sodium hyaluronate gel and regenerative microspheres, and after the formed mixed gel is injected into the skin, it can replace the lost collagen and stimulate the regeneration of collagen in the human body, with significant and lasting effects. The sodium hyaluronate composite gel product loaded with degradable microspheres for injection provided by the present invention has uniform and fine particles, is easy to inject, has a long local action time, good plasticity, and obvious filling effect.

附图说明BRIEF DESCRIPTION OF THE DRAWINGS

图1为本发明实施例1制备的微球的电镜图;FIG1 is an electron microscope image of microspheres prepared in Example 1 of the present invention;

图2(a)、(b)为本发明实施例1、对比例1、2所制备产品粘性模量和弹性模量的对比图;Figure 2 (a) and (b) are comparison diagrams of the viscous modulus and elastic modulus of the products prepared in Example 1 and Comparative Examples 1 and 2 of the present invention;

图3为本发明实施例1、对比例1、2所制备产品动力黏度的对比图;FIG3 is a comparison chart of the dynamic viscosity of the products prepared in Example 1 and Comparative Examples 1 and 2 of the present invention;

图4为本发明实施例1、对比例1、2所制备产品最大推挤力及平均推挤力的对比图。FIG4 is a comparison chart of the maximum pushing force and the average pushing force of the products prepared in Example 1 of the present invention and Comparative Examples 1 and 2.

具体实施方式DETAILED DESCRIPTION

以下结合说明书附图,通过具体实施例,对本发明的技术方案作进一步地说明,本发明决非限于实施例。The technical solution of the present invention is further described below through specific embodiments in conjunction with the accompanying drawings of the specification, but the present invention is by no means limited to the embodiments.

实施例1Example 1

(1)聚左旋乳酸微球的制备:将50g分子量为90,000Da的聚左旋乳酸加入到500mL二氯甲烷中溶解作为油相,然后缓慢加至3000mL质量分数为2.0%的聚乙烯醇水溶液中,加入完毕后,转速2500rpm/min下常温乳化30min,再持续搅拌挥发去除二氯甲烷溶液,清洗后,抽滤得到滤饼,干燥筛分得到粒径为10~50μm的聚左旋乳酸微球,采用电镜观察聚左旋乳酸微球的表面形貌结构,如图1所示。(1) Preparation of poly (L-lactic acid) microspheres: 50 g of poly (L-lactic acid) with a molecular weight of 90,000 Da was added to 500 mL of dichloromethane to dissolve as the oil phase, and then slowly added to 3000 mL of a 2.0% polyvinyl alcohol aqueous solution. After the addition was completed, the mixture was emulsified at room temperature at a speed of 2500 rpm/min for 30 min, and then the dichloromethane solution was evaporated by continuous stirring. After washing, the filter cake was obtained by suction filtration, and dried and sieved to obtain poly (L-lactic acid) microspheres with a particle size of 10 to 50 μm. The surface morphology of the poly (L-lactic acid) microspheres was observed by electron microscopy, as shown in FIG1 .

(2)交联透明质酸钠凝胶的制备:将3.6g分子量为2,000,000Da的透明质酸钠干粉溶解于50mL浓度为0.2mol/L的氢氧化钠溶液中,待透明质酸钠完全溶解后,再加入110μL二乙烯基砜,搅拌12min后将其转移至2~8℃环境中静置16h左右,得到交联的透明质酸钠凝胶。(2) Preparation of cross-linked sodium hyaluronate gel: 3.6 g of sodium hyaluronate dry powder with a molecular weight of 2,000,000 Da was dissolved in 50 mL of 0.2 mol/L sodium hydroxide solution. After the sodium hyaluronate was completely dissolved, 110 μL of divinyl sulfone was added. After stirring for 12 min, the mixture was transferred to an environment of 2 to 8 °C and allowed to stand for about 16 h to obtain a cross-linked sodium hyaluronate gel.

(3)交联凝胶的模块化制备:将步骤(2)得到的交联透明质酸钠凝胶置于超纯水中纯化透析4天,透析结束后取出交联凝胶,先放入-80℃的冷冻柜中急冻,再使用冷冻干燥机进行冷冻干燥,冻干温度为-40℃,并将得到白色固体密封存储于-80℃的冷冻柜中。(3) Modular preparation of cross-linked gel: The cross-linked sodium hyaluronate gel obtained in step (2) was purified and dialyzed in ultrapure water for 4 days. After the dialysis, the cross-linked gel was taken out and firstly placed in a -80°C freezer for quick freezing, and then freeze-dried using a freeze dryer at a freeze-drying temperature of -40°C. The obtained white solid was sealed and stored in a -80°C freezer.

(4)注射用装载可降解微球的透明质酸钠复合凝胶的制备:取1.0g冻干凝胶颗粒,加入55mL磷酸盐缓冲液,以140rpm/min的转速搅拌复溶6~8h,使交联凝胶充分溶胀。在转速6000rpm/min,压力0.08MPa的条件下,将复溶后的凝胶剪切分散。取50g剪切均质后的交联透明质酸钠凝胶,加入10g聚左旋乳酸微球,5.5g质量分数为2%的透明质酸钠流动相,30%的盐酸利多卡因溶液0.8mL,再加入0.4mL 1%的氢氧化钠溶液调节pH至6.0~7.5,加入2mL磷酸缓冲液调节渗透压至260~350mOsm/L,转速120rpm/min下搅拌8h~9h至混合均匀。然后将其罐装至预灌封注射器中,并进行离心沉降以消除气泡,用温度为121℃的高压蒸汽灭菌15min,得到注射用装载可降解微球的透明质酸钠复合凝胶,该制备过程用时3天。(4) Preparation of sodium hyaluronate composite gel loaded with degradable microspheres for injection: Take 1.0g of freeze-dried gel particles, add 55mL of phosphate buffer, and stir at a speed of 140rpm/min for 6-8h to fully swell the cross-linked gel. Shear and disperse the re-dissolved gel at a speed of 6000rpm/min and a pressure of 0.08MPa. Take 50g of cross-linked sodium hyaluronate gel after shearing and homogenization, add 10g of poly-L-lactic acid microspheres, 5.5g of 2% sodium hyaluronate mobile phase, 0.8mL of 30% lidocaine hydrochloride solution, and then add 0.4mL of 1% sodium hydroxide solution to adjust the pH to 6.0-7.5, add 2mL of phosphate buffer to adjust the osmotic pressure to 260-350mOsm/L, and stir at a speed of 120rpm/min for 8h-9h until mixed evenly. Then, it was filled into a prefilled syringe and centrifuged to eliminate bubbles. It was sterilized with high-pressure steam at a temperature of 121° C. for 15 minutes to obtain a sodium hyaluronate composite gel loaded with degradable microspheres for injection. The preparation process took 3 days.

实施例2Example 2

(1)聚左旋乳酸微球及交联透明质酸钠凝胶的制备步骤同实施例1。(1) The preparation steps of poly-L-lactic acid microspheres and cross-linked sodium hyaluronate gel are the same as those in Example 1.

(2)交联透明质酸钠凝胶的制备:将1.6g分子量为2,000,000Da的透明质酸钠干粉溶解于50mL浓度为0.4mol/L的氢氧化钠溶液中,待透明质酸钠完全溶解后,再加入130μL二乙烯基砜,搅拌12min后将其转移至2~8℃环境中静置16h左右,得到交联的透明质酸钠凝胶。(2) Preparation of cross-linked sodium hyaluronate gel: Dissolve 1.6 g of sodium hyaluronate dry powder with a molecular weight of 2,000,000 Da in 50 mL of 0.4 mol/L sodium hydroxide solution. After the sodium hyaluronate is completely dissolved, add 130 μL of divinyl sulfone. After stirring for 12 min, transfer the mixture to an environment of 2 to 8 °C and let it stand for about 16 h to obtain a cross-linked sodium hyaluronate gel.

(3)交联凝胶的模块化制备:将步骤(2)得到的交联透明质酸钠凝胶置于超纯水中纯化透析4天,透析结束后取出交联凝胶,先放入-80℃的冷冻柜中急冻,再使用冷冻干燥机进行冷冻干燥,冻干温度为-50℃,并将得到白色固体密封存储于-20℃的冷冻柜中。(3) Modular preparation of cross-linked gel: The cross-linked sodium hyaluronate gel obtained in step (2) was purified and dialyzed in ultrapure water for 4 days. After the dialysis, the cross-linked gel was taken out and firstly placed in a -80°C freezer for quick freezing, and then freeze-dried using a freeze dryer at a freeze-drying temperature of -50°C. The obtained white solid was sealed and stored in a -20°C freezer.

(4)注射用装载可降解微球的透明质酸钠复合凝胶的制备:取1.0g冻干凝胶颗粒(冻干颗粒存储时间为0d),加入55mL生理盐水,以140rpm/min的转速搅拌复溶6~8h,使交联凝胶充分溶胀。在转速6000rpm/min,压力0.08MPa的条件下,将复溶后的凝胶剪切分散。取50g剪切均质后的交联透明质酸钠凝胶,加入16g聚左旋乳酸微球,5.5g质量分数为2%的透明质酸钠流动相,30%的盐酸利多卡因溶液0.8mL,再加入0.4mL 1%的氢氧化钠溶液调节pH至6.0~7.5,加入2mL磷酸缓冲液调节渗透压至260~350mOsm/L,转速120rpm/min下搅拌8h~9h至混合均匀。然后将其罐装至预灌封注射器中,并进行离心沉降以消除气泡,用温度为121℃的高压蒸汽灭菌15min,得到注射用装载可降解微球的透明质酸钠复合凝胶,该制备过程用时3天。(4) Preparation of sodium hyaluronate composite gel loaded with degradable microspheres for injection: Take 1.0g of freeze-dried gel particles (freeze-dried particles storage time is 0d), add 55mL of normal saline, stir at a speed of 140rpm/min for 6-8h to fully swell the cross-linked gel. Shear and disperse the reconstituted gel at a speed of 6000rpm/min and a pressure of 0.08MPa. Take 50g of cross-linked sodium hyaluronate gel after shearing and homogenization, add 16g of poly-L-lactic acid microspheres, 5.5g of 2% sodium hyaluronate mobile phase, 0.8mL of 30% lidocaine hydrochloride solution, and then add 0.4mL of 1% sodium hydroxide solution to adjust the pH to 6.0-7.5, add 2mL of phosphate buffer to adjust the osmotic pressure to 260-350mOsm/L, and stir at a speed of 120rpm/min for 8h-9h until mixed evenly. Then, it was filled into a prefilled syringe and centrifuged to eliminate bubbles. It was sterilized with high-pressure steam at a temperature of 121° C. for 15 minutes to obtain a sodium hyaluronate composite gel loaded with degradable microspheres for injection. The preparation process took 3 days.

实施例3Example 3

(1)聚左旋乳酸微球及交联透明质酸钠凝胶的制备步骤同实施例1。(1) The preparation steps of poly-L-lactic acid microspheres and cross-linked sodium hyaluronate gel are the same as those in Example 1.

(2)交联透明质酸钠凝胶的制备:将3.6g分子量为2,000,000Da的透明质酸钠干粉溶解于50mL浓度为0.2mol/L的氢氧化钠溶液中,待透明质酸钠完全溶解后,再加入110μL二乙烯基砜,搅拌12min后将其转移至2~8℃环境中静置16h左右,得到交联的透明质酸钠凝胶。(2) Preparation of cross-linked sodium hyaluronate gel: 3.6 g of sodium hyaluronate dry powder with a molecular weight of 2,000,000 Da was dissolved in 50 mL of 0.2 mol/L sodium hydroxide solution. After the sodium hyaluronate was completely dissolved, 110 μL of divinyl sulfone was added. After stirring for 12 min, the mixture was transferred to an environment of 2 to 8 °C and allowed to stand for about 16 h to obtain a cross-linked sodium hyaluronate gel.

(3)交联凝胶的模块化制备:将步骤(2)得到的交联透明质酸钠凝胶置于超纯水中纯化透析4天,透析结束后取出交联凝胶,先放入-80℃的冷冻柜中急冻,再使用冷冻干燥机进行冷冻干燥,冻干温度为-80℃,并将得到白色固体密封存储于-20℃的冷冻柜中。(3) Modular preparation of cross-linked gel: The cross-linked sodium hyaluronate gel obtained in step (2) was purified and dialyzed in ultrapure water for 4 days. After the dialysis, the cross-linked gel was taken out and firstly placed in a -80°C freezer for quick freezing, and then freeze-dried using a freeze dryer at a freeze-drying temperature of -80°C. The obtained white solid was sealed and stored in a -20°C freezer.

(4)注射用装载可降解微球的透明质酸钠复合凝胶的制备:取1.0g冻干凝胶颗粒,加入75mL磷酸缓冲液,以140rpm/min的转速搅拌复溶6~8h,使交联凝胶充分溶胀。在转速6000rpm/min,压力0.08MPa的条件下,将复溶后的凝胶剪切分散。取70g剪切均质后的交联透明质酸钠凝胶,加入9g聚左旋乳酸微球,5.5g质量分数为2%的透明质酸钠流动相,30%的盐酸利多卡因溶液0.8mL,再加入0.4mL 1%的氢氧化钠溶液调节pH至6.0~7.5,加入2mL磷酸缓冲液调节渗透压至260~350mOsm/L,转速120rpm/min下搅拌8h~9h至混合均匀。然后将其罐装至预灌封注射器中,并进行离心沉降以消除气泡,用温度为121℃的高压蒸汽灭菌15min,得到注射用装载可降解微球的透明质酸钠复合凝胶,该制备过程用时3天。(4) Preparation of sodium hyaluronate composite gel loaded with degradable microspheres for injection: 1.0 g of freeze-dried gel particles were added to 75 mL of phosphate buffer and stirred at a speed of 140 rpm/min for 6 to 8 hours to fully swell the cross-linked gel. The reconstituted gel was sheared and dispersed at a speed of 6000 rpm/min and a pressure of 0.08 MPa. 70 g of cross-linked sodium hyaluronate gel after shearing and homogenization was added to 9 g of poly-L-lactic acid microspheres, 5.5 g of 2% sodium hyaluronate mobile phase, 0.8 mL of 30% lidocaine hydrochloride solution, and then 0.4 mL of 1% sodium hydroxide solution was added to adjust the pH to 6.0 to 7.5, and 2 mL of phosphate buffer was added to adjust the osmotic pressure to 260 to 350 mOsm/L, and stirred at a speed of 120 rpm/min for 8 to 9 hours until the mixture was uniformly mixed. Then, it was filled into a prefilled syringe and centrifuged to eliminate bubbles. It was sterilized with high-pressure steam at a temperature of 121° C. for 15 minutes to obtain a sodium hyaluronate composite gel loaded with degradable microspheres for injection. The preparation process took 3 days.

对比例1Comparative Example 1

(1)聚左旋乳酸微球及交联透明质酸钠凝胶的制备步骤同实施例1。(1) The preparation steps of poly-L-lactic acid microspheres and cross-linked sodium hyaluronate gel are the same as those in Example 1.

(2)装载可降解微球的透明质酸钠复合凝胶的模块化制备:该制备步骤与实施例1仅存在冻干凝胶颗粒存储时间的差异,取用的冻干凝胶颗粒存储时间为30d,其余制备工艺与实施例1相同。(2) Modular preparation of sodium hyaluronate composite gel loaded with degradable microspheres: The preparation steps are different from those in Example 1 only in the storage time of the freeze-dried gel particles. The storage time of the freeze-dried gel particles used is 30 days, and the rest of the preparation process is the same as that in Example 1.

对比例2Comparative Example 2

(1)聚左旋乳酸微球的制备步骤同实施例1。(1) The preparation steps of poly-L-lactic acid microspheres are the same as those in Example 1.

(2)交联透明质酸钠凝胶的制备以及注射用装载可降解微球的透明质酸钠复合凝胶的制备与实施例1无显著差异,该对比例制备工艺与实施例1差异主要体现在该对比例未引入实施例1步骤(3)的冻干工艺,整个复合凝胶的制备过程所需时间为7天,其余技术特征与实施例1相同。(2) The preparation of the cross-linked sodium hyaluronate gel and the preparation of the sodium hyaluronate composite gel loaded with degradable microspheres for injection were not significantly different from those in Example 1. The difference between the preparation process of this comparative example and that of Example 1 was mainly reflected in that the freeze-drying process of step (3) of Example 1 was not introduced into this comparative example. The time required for the preparation of the entire composite gel was 7 days. The remaining technical features were the same as those in Example 1.

SEM测试:对样品进行喷金处理,采用扫描电镜表征PLLA微球的表面微观形貌,加速电压为5kV,结果见图1。从图中可以看出,PLLA微球表面光滑,颗粒均一,粒径均在10~50μm的范围内。SEM test: The sample was treated with gold spraying, and the surface morphology of the PLLA microspheres was characterized by scanning electron microscopy, with an acceleration voltage of 5 kV. The results are shown in Figure 1. As can be seen from the figure, the surface of the PLLA microspheres is smooth, the particles are uniform, and the particle size is in the range of 10 to 50 μm.

流变学测试:采用流变仪,在25℃下,0.05~10Hz范围内,测定实施例1与对比例1、2的粘性模量和弹性模量;在剪切速率为0.1~10s-1(25±0.1)℃条件下,测定实施例1与对比例1、2的动力黏度,结果见图2、图3。从图中可以看出,实施例1和对比例1比较,交联透明质酸钠凝胶经过冻干处理后立即复溶及冻干后放置30天再复溶,两组复合凝胶在粘性模量、弹性模量和动力黏度曲线具有高度重合性,无明显差异,说明透明质酸钠凝胶交联模块化制备对复合凝胶理化性能无影响。Rheological test: The viscous modulus and elastic modulus of Example 1 and Comparative Examples 1 and 2 were measured by a rheometer at 25°C and in the range of 0.05-10 Hz; the dynamic viscosity of Example 1 and Comparative Examples 1 and 2 was measured at a shear rate of 0.1-10s -1 (25±0.1)°C, and the results are shown in Figures 2 and 3. As can be seen from the figure, compared with Example 1 and Comparative Example 1, the cross-linked sodium hyaluronate gel was immediately re-dissolved after freeze-drying and was placed for 30 days after freeze-drying and then re-dissolved. The two groups of composite gels have a high degree of overlap in the viscous modulus, elastic modulus and dynamic viscosity curves, and there is no obvious difference, indicating that the modular preparation of cross-linked sodium hyaluronate gel has no effect on the physical and chemical properties of the composite gel.

推挤力测试:采用万能材料试验机,将样品置于室温环境平衡后,在推挤速度为30mm/min条件下,测定实施例1与对比例1、2的推挤力,结果见图4。从图中可以看出,对比实施例1与对比例1、2的最大及平均推挤力数值,实施例1与对比例1推挤力偏差均小于0.5N;此外,实施例1与对比例1的推挤力均低于对比例2,在15~20N之间,说明采用化学交联模块化处理的方式制备的复合凝胶推挤力稳定,且更易于注射推注。Pushing force test: After the samples were placed in a room temperature environment for equilibrium using a universal material testing machine, the pushing forces of Example 1 and Comparative Examples 1 and 2 were measured at a pushing speed of 30 mm/min, and the results are shown in Figure 4. As can be seen from the figure, by comparing the maximum and average pushing force values of Example 1 with those of Comparative Examples 1 and 2, the pushing force deviations of Example 1 and Comparative Example 1 are both less than 0.5 N; in addition, the pushing forces of Example 1 and Comparative Example 1 are both lower than those of Comparative Example 2, ranging from 15 to 20 N, indicating that the composite gel prepared by chemical cross-linking modular treatment has stable pushing force and is easier to inject.

此外,经化学交联模块化处理的复合凝胶在室温下放置30天后,外观上仍呈均一的乳白色凝胶,无分层现象,与2~8℃环境下保存的复合凝胶相比无明显差异。从表1可以看出,对比例1在室温环境下放置30天前后的动力黏度指标仅下降了4.46%,在误差范围内,说明复合凝胶未发生降解,状态稳定。In addition, after the composite gel treated with chemical cross-linking modularization was placed at room temperature for 30 days, it still appeared as a uniform milky white gel in appearance without stratification, and there was no significant difference compared with the composite gel stored at 2-8°C. As can be seen from Table 1, the dynamic viscosity index of Comparative Example 1 only decreased by 4.46% before and after being placed at room temperature for 30 days, which is within the error range, indicating that the composite gel has not been degraded and is in a stable state.

表1Table 1

复合凝胶Composite gel 评估指标Evaluation Metrics 0d0d 30d30d 变化率Rate of change 时长/dDuration/d 对比例1Comparative Example 1 动力黏度Dynamic viscosity 232,212232,212 221,841221,841 -4.46%-4.46% 3030

以上所述的实施例仅是对本发明的优选实施方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。The embodiments described above are only descriptions of the preferred implementation modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims (10)

1.一种注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,包括如下步骤:1. A modular preparation method for a sodium hyaluronate composite gel loaded with degradable microspheres for injection, characterized in that it comprises the following steps: 1)透明质酸钠在碱性溶液中溶解后进行交联反应,并将交联形成的透明质酸钠凝胶透析4~8天后进行冷冻干燥得到冻干凝胶;1) Sodium hyaluronate is dissolved in an alkaline solution and then cross-linked, and the cross-linked sodium hyaluronate gel is dialyzed for 4 to 8 days and then freeze-dried to obtain a freeze-dried gel; 2)将冻干凝胶粉碎为凝胶微粒,将凝胶微粒以一定浓度充分复溶后,得到交联凝胶,在交联凝胶中加入特定比例的微球及透明质酸钠溶液混合均匀得混合凝胶;2) crushing the freeze-dried gel into gel particles, fully re-dissolving the gel particles at a certain concentration to obtain a cross-linked gel, adding microspheres and sodium hyaluronate solution in a specific ratio to the cross-linked gel and mixing them evenly to obtain a mixed gel; 3)将混合凝胶灌装至预灌封注射器中,进行高压蒸汽灭菌,得到注射用装载可降解微球的透明质酸钠复合凝胶。3) Filling the mixed gel into a pre-filled syringe and sterilizing it with high-pressure steam to obtain a sodium hyaluronate composite gel loaded with degradable microspheres for injection. 2.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述的交联凝胶的冷冻干燥温度为-50~-80℃,存储温度为0~-80℃,冻干凝胶的复溶溶液为磷酸缓冲盐或生理盐水,pH为6.8~7.5,渗透压为280~340mOsm/L。2. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1 is characterized in that the freeze-drying temperature of the cross-linked gel is -50 to -80°C, the storage temperature is 0 to -80°C, the reconstitution solution of the freeze-dried gel is phosphate buffered saline or physiological saline, the pH is 6.8 to 7.5, and the osmotic pressure is 280 to 340 mOsm/L. 3.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述微球材料占混合凝胶的质量分数为5~30%;所述微球材料的平均粒径为10~100μm。3. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1 is characterized in that the mass fraction of the microsphere material in the mixed gel is 5 to 30%; and the average particle size of the microsphere material is 10 to 100 μm. 4.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述碱性溶液为氢氧化钠、氢氧化钾中的任意一种,溶液浓度为0.1~5.0mol/L。4. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1, characterized in that the alkaline solution is any one of sodium hydroxide and potassium hydroxide, and the solution concentration is 0.1 to 5.0 mol/L. 5.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述步骤2)中加入的透明质酸钠的分子量为500,000~3,000,000Da,交联凝胶中透明质酸钠的浓度为1~15%,透明质酸钠在混合凝胶中的质量分数为1~50%。5. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1, characterized in that the molecular weight of the sodium hyaluronate added in step 2) is 500,000 to 3,000,000 Da, the concentration of sodium hyaluronate in the cross-linked gel is 1 to 15%, and the mass fraction of sodium hyaluronate in the mixed gel is 1 to 50%. 6.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述的步骤1)中的透明质酸钠凝胶交联反应所用的交联剂为二乙烯基砜、1,4-丁二醇二缩水甘油醚、乙二酸二酰肼、碳二亚胺、甲基丙烯酸缩水甘油酯中的一种或多种,浓度为0.1~10mg/mL。6. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1, characterized in that the cross-linking agent used in the cross-linking reaction of the sodium hyaluronate gel in the step 1) is one or more of divinyl sulfone, 1,4-butanediol diglycidyl ether, oxalic acid dihydrazide, carbodiimide, and glycidyl methacrylate, and the concentration is 0.1 to 10 mg/mL. 7.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述的步骤2)中微球分批、多次加入凝胶体系,在100~800rpm/min下搅拌4~16小时,且每隔20~50分钟手动搅拌一次,使复合凝胶体系均匀混合。7. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1 is characterized in that in the step 2), the microspheres are added to the gel system in batches and multiple times, stirred at 100-800 rpm/min for 4-16 hours, and manually stirred every 20-50 minutes to make the composite gel system evenly mixed. 8.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述透明质酸钠凝胶成分包括透明质酸钠、交联透明质酸钠,透明质酸钠可替换为胶原蛋白、壳聚糖、明胶、海藻酸钠、纤维蛋白、丝素蛋白以及人工合成凝胶,所述的人工合成凝胶为聚乙二醇、聚乙烯醇、聚氧乙烯、聚丙烯酰胺中的任意一种。8. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1, characterized in that the sodium hyaluronate gel component includes sodium hyaluronate and cross-linked sodium hyaluronate, and sodium hyaluronate can be replaced by collagen, chitosan, gelatin, sodium alginate, fibrin, silk fibroin and artificial synthetic gel, and the artificial synthetic gel is any one of polyethylene glycol, polyvinyl alcohol, polyethylene oxide and polyacrylamide. 9.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述的微球的材料为聚乳酸、聚左旋乳酸、聚己内酯、羟基磷灰石中的一种或几种的复合体。9. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1, characterized in that the material of the microspheres is a composite of one or more of polylactic acid, poly-L-lactic acid, polycaprolactone, and hydroxyapatite. 10.根据权利要求1所述的注射用装载可降解微球的透明质酸钠复合凝胶的模块化制备方法,其特征在于,所述的步骤2)中在交联凝胶中还加入脂质体、外泌体、氨基酸、多肽、蛋白质、维生素及局部类麻醉剂等一种或多种活性成分。10. The modular preparation method of the sodium hyaluronate composite gel loaded with degradable microspheres for injection according to claim 1, characterized in that in the step 2), one or more active ingredients such as liposomes, exosomes, amino acids, polypeptides, proteins, vitamins and local anesthetics are also added to the cross-linked gel.
CN202410966599.8A 2024-07-18 2024-07-18 Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection Pending CN118903551A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410966599.8A CN118903551A (en) 2024-07-18 2024-07-18 Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410966599.8A CN118903551A (en) 2024-07-18 2024-07-18 Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection

Publications (1)

Publication Number Publication Date
CN118903551A true CN118903551A (en) 2024-11-08

Family

ID=93295190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410966599.8A Pending CN118903551A (en) 2024-07-18 2024-07-18 Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection

Country Status (1)

Country Link
CN (1) CN118903551A (en)

Similar Documents

Publication Publication Date Title
US11590259B2 (en) Composition and kits for pseudoplastic microgel matrices
CN108478867B (en) Injectable polymer hydrogel based on acylhydrazone bond, its preparation method and polymer hydrogel injection
RU2683286C2 (en) Method for crosslift of hyaluronic acid, method for preparation of injection hydrogel, hydrogel and use thereof
EP3865156B1 (en) Sustained-release injection formulation comprising conjugate of poly-l-lactic acid filler and hyaluronic acid filler and bioactive materials, and preparation method thereof
US20230069580A1 (en) Chemically cross-linked hydrogel and its microspheres, preparation method and application
US20120301436A1 (en) Polyelectrolyte complex gels and soft tissue augmentation implants comprising the same
EP2405936B1 (en) Injectable biomaterials
CN112851983B (en) Electrostatic spraying film of hydrogel and preparation method and application thereof
JP2018511622A5 (en)
EP3851130B1 (en) Injection formulation containing poly-l-lactic acid filler and hyaluronic acid filler conjugate, and method for preparing same
CN113877000B (en) Microsphere composition for injection and application thereof
CN115584037A (en) Crosslinked gel material containing polymer microspheres, preparation method thereof and injection filler
CN117769438A (en) Derivatized or rapidly polymerizable collagen compositions for tissue augmentation comprising non-absorbable or slowly absorbable polymers
CN118434459A (en) Soft tissue augmentation using injectable, neutral pH soluble collagen-glycosaminoglycan compositions
CN116173293A (en) Composite gel, preparation method and application
CN116370707A (en) A kind of injection filler and preparation method thereof
CN115317665B (en) Polyester particle composite temperature-sensitive instant gel subcutaneous implant
CN114395164B (en) Polysaccharide composite gel and preparation method and application thereof
CN118320184A (en) Injectable exosome-loaded silk fibroin microsphere-carboxymethyl cellulose composite gel and preparation method and application thereof
CN118903551A (en) Modularized preparation method of sodium hyaluronate composite gel loaded with degradable microspheres for injection
CN117298332A (en) Injectable double-network hydrogel with immune regulation function and preparation method and application thereof
CN116672498B (en) Composite material for injection and application thereof
CN118384329B (en) An injectable composite filler and a preparation method thereof
CN116271224B (en) A soft tissue regeneration filler and preparation method thereof
CN117582548A (en) An injectable multi-crosslinked composite hydrogel scaffold with the function of in-situ repair of anterior cruciate ligament and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination